Are Reports of Randomized Controlled Trials Improving over Time? A Systematic Review of 284 Articles Published in High-Impact General and Specialized Medical Journals

Matthew J. To, Jennifer Jones, Mohamed Emara, Alejandro R. Jadad

Introduction

Since its publication in 1996, the Consolidated Standards of Reporting Trials (CONSORT) statement has been endorsed by over 400 journals worldwide, is available in seven different languages, and is viewed through its website more than 100,000 times each year. [1], [2].

Despite this high level of endorsement and dissemination, studies have suggested that inadequate reporting is still highly prevalent, even among journals that have endorsed the CONSORT statement calling for the evaluation of the impact of such reporting guidelines over a long period of time. [3], [4] Research also suggests that reporting quality varies according to the type of journal, with RCTs published in general journals having higher reported quality than those in specialized journals. [5] This study was designed to assess the quality of reports of RCTs evaluating interventions for chronic diseases that were published from 1995 to 2010 in high-impact journals that claim to have adopted the CONSORT statement.

The study only focuses on the quality of the reports of RCTs, not the quality of the RCTs as a whole, because the latter is likely an impossible undertaking. Quality, as beauty, anxiety, happiness, or love, is in the eye of the beholder, and means different things to different people, at different times, with different needs. [6]
Therefore, this article provides data on key variables that have been empirically associated with an increased likelihood of bias in the original research effort, which could be easily reported by authors, and which could be easily identified as present or absent by readers.

**Methods**

**Information Sources**

The sample was drawn from a study designed to establish the frequency with which people living with multiple chronic diseases are excluded from RCTs published in high citation impact journals [7].

The trials were identified through MEDLINE and reports were included in the review if they:

- Described RCTs published from January to March of 1995, 2000, 2005, and 2010 in the five highest-impact factor general medical journals (BMJ, CMAJ, JAMA, Lancet, and NEJM) and specialized journals (American Journal of Respiratory and Critical Care Medicine, Archives of General Psychiatry, Circulation, Diabetes, and Journal of Clinical Oncology), and

- Provided original data on the effects of interventions for chronic conditions (any incurable or long-lasting condition) in adults.

Trials on pediatric populations, post-trial follow-up studies, or secondary sub-group analyses were excluded.

**Data Extraction**

Data extraction forms were piloted by members of the research team. Data were extracted and coded by two independent observers on the following variables: title; publication date; first author’s surname; country where the study was performed or coordinated (if multicenter); study design; and description of allocation concealment. Quality scores using the Jadad Scale were calculated from its individual items (descriptions of randomization, blinding, withdrawals and dropouts in RCT reports). As trials that were not randomized were excluded, scores of 1 to 2 out of 5 were regarded as indicating low quality. [8] Data were also obtained on whether the trial presented a participant flow diagram. Discrepancies were resolved by consensus by a third person whenever necessary.

**Data Synthesis**

Descriptive statistics were used to summarize all quantitative variables. Comparisons between general medical and specialized journals, and trends over time were performed using Chi-square tests. All statistical tests were two-tailed and a p value lower than 0.05 was considered as statistically significant.

**Results**

The search yielded 3854 potentially eligible articles. After screening their titles and abstracts, 284 reports were selected for inclusion in the analysis (Figure 1).

Of those included, 165 of the trials were published in specialized journals (58.1%). Most of the studies used parallel study design (38.4%) and were conducted or coordinated in North America (48.2%) or Europe (46.5%). The majority of the reports (36.3%) received quality scores compatible with low methodological quality. Trials published in general medical journals had higher quality scores than those in specialized journals (55.5% vs. 35.2%) had high quality scores, respectively, with p = 0.001), reported adequate concealment of allocation more often (50.4% vs. 35.8%, p = 0.013), and included a trial participant flow diagram more often (57.1% vs. 32.1%, p<0.001) (Table 1). There was a significantly higher proportion of reports with high quality scores over time (29% in 1995, 42% in 2000, 48.7% in 2005, 51.9% in 2010, p = 0.038) with the largest improvement occurring between 1995 and 2000. There were significant improvements in reporting of allocation concealment (32.3% in 1995, 31.9% in 2000, 42.1% in 2005, and 58.4% in 2010, p = 0.003) and presentation of a trial flow diagram (6.5% in 1995, 29.0% in 2000, 42.1% in 2005, and 84.4% in 2010, p<0.001) with the largest improvements occurring between 2005 and 2010 (Figure 2). Upon further analysis, there was a significantly higher proportion of reports published in general medical journals with high quality scores over time (21.9% in 1995, 56.0% in 2000, 67.9% in 2005, and 76.5% in 2010, p<0.001) while no significant differences in the proportion of reports published in specialized journals with high quality scores were observed over time (36.7% in 1995, 34.1% in 2000, 37.5% in 2005, and 32.6% in 2010, p = 0.961) (Table 2). Although reporting of allocation concealment in general medical journals improved over time, these differences were not significant (34.4% in 1995, 48.0% in 2000, 53.6% in 2005, and 64.7% in 2010, p = 0.10). Reporting of allocation concealment in specialized journals significantly improved over time (30.0% in 1995, 22.7% in 2000, 35.4% in 2005, 53.5% in 2010, p = 0.023). The inclusion of trial flow diagrams improved significantly over time for general medical journals (6.3% in 1995, 64.0% in 2000, 75.0% in 2005, 85.3% in 2010, p<0.001) and specialized journals (6.7% in 1995, 9.1% in 2000, 22.9% in 2005, 83.7% in 2010, p<0.001).

**Discussion**

In this review, we present the results of one of the largest efforts to date to assess the reported quality of RCTs since the publication of the CONSORT statement. Our findings suggest that reporting quality of RCTs in the highest impact journals has improved significantly over the last fifteen years. The largest improvement was seen in the 13-fold jump in inclusion of a trial participant flow
diagram (from 6.5% in 1995 to 84.4% in 2010) which could be attributed to the endorsement of the CONSORT diagram by most of the high impact journals included in the study and the development of international initiatives to improve reporting quality such as EQUATOR. [9] Although significant improvements in the number of trials with description of allocation concealment and with high quality scores were also observed over time, these two variables displayed different trends. Adequate description of allocation concealment improved considerably over the fifteen years with steady improvements at each successive time point, exceeding in 2010 what has been previously reported. [10], [11] Although an increasing trend of high-quality trials was observed over time, this increase appears to be leveling off with time, as there was only a 3% increase in the proportion of high-quality reports published between 2005 and 2010.

Although this study only examined selected items from reports of RCTs on interventions for chronic diseases published in high-impact journals, the findings appear consistent with previous

| Table 1. Report Characteristics by Type of Journal. |
|--------------------------------------------------|
| **General Medical Journal** *(N = 119)* | **Specialized Journal** *(N = 165)* | $\chi^2$ Value | P Value |
| Quality Score | No. (%) | No. (%) | 13.558 | 0.009 |
| 1 | 21 (17.6) | 44 (26.7) | 11.596 | 0.001 |
| 2 | 32 (26.9) | 63 (38.2) | 6.106 | 0.013 |
| 3 | 40 (33.6) | 37 (2.4) | 11.701 | <0.001 |
| 4 | 15 (12.6) | 16 (9.7) | 5 (9.2) | 5 (3.0) |
| 5 | 11 (9.2) | 0.009 | 0.009 | 0.009 |

Quality of Trial Reports: A Systematic Review

Figure 2. Quality scores, reporting of allocation concealment, and inclusion of trial flow diagram significantly improved over time.  

![Figure 2](https://doi.org/10.1371/journal.pone.0084779.g002)
research, suggesting that there have been improvements in reporting quality of RCTs in the biomedical literature as a whole, [12], [13] with RCTs published in CONSORT endorsing journals having relatively higher reported quality than reports published in non-CONSORT endorsing journals. [14] However, despite this encouraging trend, significant differences remain between general and specialized journals, with ample room for improvement, even among the former. Our findings are consistent with previous research showing that over half of the articles published in high-impact general medical journals reported adequate allocation concealment, [15] or that reports published in the specialist literature have shown little or no improvement since the development of the CONSORT statement. [16–19] Indeed, even those specialized journals that claim to support the CONSORT statement. However, there is still much room for improvement, especially among specialized journals.

As this study was limited to assessment of several selected reporting items, additional analyses of various components of reported quality would yield more insights into the shortcomings of reporting of trials.

Poor compliance with reporting standards by authors and journal editors, just as poor adherence to therapies by patients or to clinical practice guidelines by clinicians, is becoming a chronic challenge for which effective interventions are urgently needed. Reporting guidelines such as the updated CONSORT statement, [20], [21] and the inclusion of clearer and stronger instructions to authors by journals [22] may not be sufficient.

It is important to underscore, however, that even if the reports of RCTs were perfect, such reports should not be equated with the quality of the trials themselves. There is no such thing as a perfect trial. As stated by Jadad and Enkin, [6] “To be perfect, among other things, trials would be designed in a way that would balance out all possible competing interests, and help to answer clear, relevant, previously unanswered questions. They would be conducted, and reported by researchers who did not have conflicts of interest, and who follow strict ethical principles.

They would have to evaluate all possible interventions, for all possible variations of the conditions of interest, in all possible types of patients, in all settings, using all relevant outcome measures. Moreover, they would include all available patients, and make full use of strategies to eliminate bias during the administration of the interventions, the evaluation of the outcomes, and reporting of the results, thus reflecting the true effect of the interventions.

Unfortunately, a perfect trial can only exist in our imagination. In real life, researchers can only do the best that they can, and report it as clearly as they can.”

Conclusion

We found significant improvements in reporting quality of RCTs published in high-impact factor general and specialized journals over the last fifteen years. These improvements are likely attributed to concerted international efforts to improve reporting quality such as the CONSORT Statement. However, there is still much room for improvement, especially among specialized journals.

Ethics Committee Approval

REB approval was not required or obtained for this study as it was a review of published articles and did not involve human subjects.

Supporting Information

Checklist S1.

Author Contributions

Conceived and designed the experiments: MJT JJ ARJ. Performed the experiments: MJT JJ ME. Analyzed the data: MJT JJ. Wrote the paper: MJT JJ ME ARJ.

Table 2. Report Characteristics by Type of Journal Over Time.

|                | 1995 (N = 62) | 2000 (N = 69) | 2005 (N = 76) | 2010 (N = 77) | X² Value | P Value |
|----------------|---------------|---------------|---------------|---------------|----------|---------|
|                | General | Specialized | General | Specialized | General | Specialized | General | Specialized | General | Specialized | General | Specialized | General | Specialized | General | Specialized | General | Specialized |
| Quality Score  | No. (%)     | No. (%)      | No. (%)     | No. (%)      | No. (%)     | No. (%)     | No. (%)     | No. (%)     | No. (%)     | No. (%)     |
| High           | 7 (21.9)    | 11 (36.7)    | 14 (56.0)   | 15 (34.1)    | 19 (67.9)   | 18 (37.5)   | 26 (76.5)   | 14 (32.6)   | 22.433*    | <0.001*   |
| Low            | 25 (78.1)   | 19 (63.3)    | 11 (44.0)   | 9 (32.1)     | 30 (62.5)   | 8 (23.5)    | 29 (67.4)   | 0.295**    | 0.961**   |
| Allocation Concealment | Adequate | 11 (34.4) | 9 (30.0) | 12 (48.0) | 10 (22.7) | 15 (53.6) | 17 (35.4) | 22 (64.7) | 23 (53.5) | 6.241* | 0.100* |
|                | Inadequate  | 21 (65.6)   | 21 (70.0)   | 13 (52.0)    | 34 (77.3)   | 13 (46.4)   | 31 (64.6)   | 12 (35.3)   | 20 (46.5)   | 9.572**   | 0.023** |
| Trial Flow Diagram | Yes      | 2 (6.3)     | 2 (6.7)     | 16 (64.0)    | 4 (9.1)     | 21 (75.0)   | 11 (22.9)   | 29 (85.3)   | 36 (83.7)   | 48.972*   | <0.001* |
|                | No         | 30 (93.8)   | 28 (93.3)   | 9 (36.0)     | 40 (90.9)   | 7 (25.0)    | 37 (77.1)   | 5 (14.7)    | 7 (16.3)    | 73.993**  | <0.001** |

Note: *denotes comparisons between all time points for variable in general medical journals; **denotes comparisons between all time points for variable in specialized journals.

doi:10.1371/journal.pone.0084779.t002
References

1. Begg C, Cho M, Eastwood S, Horton R, Moher D, et al. (1996) Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 276: 637–639.
2. The Consort Statement. Available: http://www.consort-statement.org/. Accessed 30 Jan 2013.
3. Chan AW, Altman DG (2005) Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 365: 1159–1162.
4. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, et al. (2006) Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust 185: 263–267.
5. Mills E, Wu P, Gagnier J, Heels-Ansdell D, Montori VM (2005) An analysis of general medical and specialist journals that endorse CONSORT found that reporting was not enforced consistently. J Clin Epidemiol 58: 662–667.
6. Jadad AR, Enkin MW (2007) Randomized controlled trials: questions, answers and musings. London: BMJ Books. 160 p.
7. Jadad AR, To MJ, Enzara M, Jones J (2011) Consideration of multiple chronic diseases in randomized controlled trials. JAMA 306: 2670–2672.
8. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1–12.
9. EQUATOR Network. Available: http://www.equator-network.org/. Accessed 31 Oct 2013.
10. Pildal J, Chan AW, Hróbjartsson A, Forfang E, Altman DG, et al. (2005) Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ 330: 1049.
11. Mills EJ, Wu P, Gagnier J, Deveraux PJ (2005) The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement. Contemp Clin Trials 26: 480–487.
12. Moher D, Jones A, Lepage L, CONSORT Group (Consolidated Standards for Reporting of Trials) (2001) Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 285: 1992–1993.
13. Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG (2010) The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ 340: c723.
14. Turner L, Moher D, Shamseer L, Weeks L, Peterx J, et al. (2011) The influence of CONSORT on the quality of reporting of randomised controlled trials: an updated review. Trials (Suppl 1): A47.
15. Hewitt C, Hahn S, Torgerson DJ, Watson J, Bland JM (2005) Adequacy and reporting of allocation concealment: review of recent trials published in four general medical journals. BMJ 330: 1057–1059.
16. Streh D, Sohmann B, Weikert B, Bauer M, Pfennig A (2011) Quality of reporting of randomized controlled trials of pharmacologic treatment of bipolar disorders: a systematic review. J Clin Psychiatry 72: 1214–1221.
17. Cavadas V, Branco F, Carvalho FL, Osório L, Gomes MJ, et al. (2011) The quality of reporting of randomized controlled trials in pelvic organ prolapse. Int Urogynecol J 22: 1117–1125.
18. Marshman Z, Farid F (2010) The quality of reporting of randomized controlled trials in dental public health. Community Dent Health 27: 253–256.
19. King DL, Delibabbrturo PH, Griffiths MD, Gradisar M (2011) Assessing clinical trials of Internet addiction treatment: a systematic review and CONSORT evaluation. Clin Psychol Rev 31: 1110–1116.
20. Schulz KF, Altman DG, Moher D, CONSORT Group (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. BMJ 340: c332.
21. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, et al. (2010) CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomized trials. BMJ 340: c809.
22. Hopewell S, Altman DG, Moher D, Schulz KF (2008) Endorsement of the CONSORT Statement by high impact factor medical journals: a survey of journal editors and journal ‘Instructions to Authors’. Trials 9: 20.